publication date: Oct. 10, 2014

html Briefs.html

Boyle Wins ESMO Lifetime Achievement Award

THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY named three winners of the society’s annual awards.

Peter Boyle received the ESMO Lifetime Achievement Award for his long-standing contribution to cancer epidemiology, education and prevention.

Carsten Bokemeyer will receive the ESMO Award for his commitment to accelerate the transition of cancer discovery into real benefit.

Heikki Joensuu was acknowledged with the Hamilton Fairley Award for his significant contribution to improve breast cancer and GIST diagnostics and care.

Boyle became the first non-medical oncologist elected to full membership of ESMO in 2006. He is currently a professor of global public health at the University of Strathclyde and holds honorary or visiting professorships at Glasgow and Yale Universities.

Boyle is founder and president of the World Prevention Alliance and inaugural director of the University of Strathclyde Institute of Global Public Health at iPRI. He led the EUROCAN+PLUS project for the European Parliament which developed priorities for coordination of cancer research in Europe and was Editor of the World Cancer Report 2008 and the State of Oncology 2013 which highlighted the growing global cancer crisis.

Bokemeyer’s discoveries include identifying the early stages of malignant germ cell transformation and the mechanisms of resistance of germ cell tumors to chemotherapy. He has also developed therapeutic concepts with cytostatic drugs and immunotherapy in solid tumors. He is currently director of the University Cancer Center Hamburg.

In 2000, Joensuu and colleagues discovered that imatinib was effective for most advanced GIST and, in 2011, he found that as adjuvant treatment … Continue reading 40-38 The Cancer Letter In Brief

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.